Ipsen posts 2012 loss on haemophilia market exit
PARIS Feb 27 (Reuters) - French drugmaker Ipsen posted a full-year net loss of 29 million euros ($37.9 million) on Wednesday that reflected its exit from the haemophilia market.
But the company said margins would remain stable in 2013 and that sales of drugs prescribed by specialist doctors would continue to grow.
The company said it expected sales of specialty care drugs to rise between 6 and 8 percent this year, while revenue from products prescribed by family doctors would decline between 6 and 8 percent as activity in France remains under pressure.
Ipsen is paying a flat dividend of 0.8 euros per share for 2012. ($1 = 0.7649 euros) (Reporting by Benjamin Mallet and Elena Berton; Editing by James Regan)
- White House reverses, says Obama met uncle and lived with him during law school
- Flights delayed as air pollution hits record in Shanghai
- South Africa mourns Mandela, will bury him on December 15 |
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Analysis: Boeing bidders dangle goodies to win 777X jetliner